ANTIHYPERTENSIVE LABELING SHOULD INCLUDE DEMONSTRATED BENEFITS OF REDUCED STROKE INCIDENCE AND CORONARY EVENTS, FDA CARDIORENAL ADVISORY CMTE. AGREES

Current antihypertensive labeling should be changed to include additional information on demonstrated clinical benefits of reduced risk of stroke and coronary events from beta blockers and diuretics, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded Oct. 20.